- Has been a contributor to LBBC since 2021
- Reports on major scientific meetings and works to ensure LBBC's web content is current
Jamie Kudera is a contributing writer for Living Beyond Breast Cancer. She reports on major scientific meetings for the LBBC community and works with LBBC to ensure that web content is current.
Jamie specializes in health and scientific writing for nonprofit organizations, universities, and hospitals. Much of her work involves communicating complex medical information to the general public. She appreciates how difficult it can be to learn of a cancer diagnosis and learn about cancer at the same time, and she hopes that her efforts help ease this experience.
Telephone coaching leads to weight loss for people with breast cancer | ASCO 2023
Much-awaited results of a clinical trial presented at the annual meeting of the American Society of Clinical Oncology on June 5, 2023 support the use of telephone-based coaching to promote weight loss in women with breast cancer.
Diclofenac prevents hand-foot syndrome side effect of capecitabine | ASCO 2023
The chemotherapy drug capecitabine (Xeloda) is often used to treat breast cancer, but for some people it can be hard to tolerate. New research reveals that diclofenac, an easily available topical gel, can help prevent one of the most challenging side effects that can happen with capecitabine.
Ribociclib on track for approval for early-stage breast cancer | ASCO 2023
People with early-stage hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer will soon have a new treatment option in ribociclib (Kisqali), now used to treat metastatic HR+, HER2- breast cancer.
Reducing ovarian function yields better outcomes for young women with breast cancer | ASCO 2023
A review of multiple studies shows benefit of ovarian function suppression or ablation for young women with early-stage, estrogen receptor-positive breast cancer or who were at risk of breast cancer recurrence.
Elacestrant on course to gain FDA approval
Elacestrant is poised to move forward as a new option for metastatic hormone receptor-positive, HER2-negative breast cancer in 2023. New results point to a relationship between the drug’s effectiveness and both the prior length of time on CDK 4/6 inhibitors and the presence of an ESR1 mutation.
Young people with early-stage breast cancer: What we learned at ASCO
Several studies presented at the 2022 Annual Meeting of the American Society of Clinical Oncology focused on ways to better tailor treatment for premenopausal women with early-stage breast cancer, especially those with hormone receptor-positive breast cancer.
Radiation may not be needed for some early-stage breast cancers
Hormonal therapy alone following surgery may be enough to prevent local recurrence in some people with early-stage hormone receptor-positive breast cancer, according to research presented at the 2022 annual meeting of the American Society of Clinical Oncology.
Growth in number of older adults with cancer requires new approaches
At the annual meeting of the American Society of Clinical Oncology, a panel of three researchers and a physician on June 3, 2022 shared findings and strategies to address the changing needs of older people with breast and other cancers. Their take-away: now is the time to join the conversation.
Black people with breast cancer want to know about clinical trials
More than 80% of Black people with metastatic breast cancer are somewhat or very likely to participate in a clinical trial, yet only 40% report having a conversation with their health care team about them, according to new patient-led research.
Advocates call on cancer community to focus on LGBTQ+ health
At a special session on gender-based and sexual orientation inequities at the 2022 gathering of the American Society for Clinical Oncology (ASCO), advocates discussed the challenges LGBTQ+ people face in cancer prevention and treatment and strategies to address them.
Anti-HER2 drug trastuzumab deruxtecan found effective for HER2-low tumors
A study presented at the 2022 meeting of the American Society of Clinical Oncology of trastuzumab deruxtecan or TDX-d (Enhertu) is very likely to change the standard of care for many people with metastatic breast cancer.
Palbociclib does not improve overall survival for metastatic breast cancer
The CDK 4/6 inhibitor palbociclib (Ibrance) did not extend overall survival when combined with hormonal therapy as a first-line treatment in people with hormone-receptor positive, HER2-negative metastatic breast cancer, according to a presentation at the 2022 meeting of the American Society of Clinical Oncology.
Black race strongest predictor of lymphedema development after treatment for breast cancer
Black women were three-and-a-half times more likely to develop lymphedema than white women following treatment for breast cancer, according to results of a prospective study presented at the San Antonio Breast Cancer Symposium on December 10.
Olaparib well tolerated in people with early-stage BRCA+, HER2- disease
Early results of a quality-of-life study presented at the 2021 San Antonio Breast Cancer Symposium found that olaparib did not worsen or prolong side effects when given after chemotherapy for BRCA+, HER2-, high-risk, early-stage breast cancer.
Patient advocates challenge oncology community to improve racial equity in clinical trials
Health disparities in breast cancer care proved to be an important part of the 2021 San Antonio Breast Cancer Symposium, especially the session on “Trust in Science," which brought together advocates, doctors, and researchers concerned about racial equity in cancer treatment.
T-DXd emerges as new standard second-line treatment for HER2+ MBC
Research presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) identified a new standard second-line treatment for metastatic disease, a more effective tyrosine kinase inhibitor, and a cell pathway for further study in HER2-positive breast cancer.
Aromatase inhibitors outperform tamoxifen in young women with ER+ breast cancer and OFS
Aromatase inhibitors are more effective than tamoxifen in preventing cancer from coming back if ovarian function is suppressed, according to research presented in two sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS).
Elacestrant improves outcomes for ER+ metastatic breast cancer
Elacestrant, an endocrine therapy taken in pill form, emerges as a new option for people with ER+/HER2- metastatic breast cancer, according to an update on the EMERALD clinical trial presented at the 2021 San Antonio Breast Cancer Symposium.
Palbociclib failed to improve outcomes in early-stage disease
The results from the much-anticipated phase III PALLAS trial, presented at the 2021 San Antonio Breast Cancer Symposium, show that palbociclib (Ibrance) does not improve outcomes for people with early-stage hormone-positive (HR+) HER2- breast cancer.
Immunotherapy drug offers effective new treatment for triple-negative breast cancer
The first day of the 2021 San Antonio Breast Cancer Symposium (SABCS) included findings from two clinical trials that show the immunotherapy drug pembrolizumab (Keytruda) offers a new treatment option for people with triple-negative breast cancer.